5Durie B G M.Salmon S E. A clinical staging system for multiple myeloma [J]. Cancer, 1975,36 : 842- 854,.
6Knudsen L M, Hippe E, Hjorth M. et al. Renal function in newly diagnosed multiple myeloma-a demographic study of 1 353 patients. The Nordic Myelonm Study Group[J]. Eur J Haematol. 1994.53(4) : 207- 212.
7Trullemans F. Schots R. Storma G. et al. Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantation [J]. Bone Marrow Transplant, 2000.25(1):115-117.
8Sirohi B, Powles R. Kulkarni S, et al. Comparison of new patients with BenceJones. lgG and IgA myeloma receiving sequential therapy, the need to regard these immunologic subtypes as separate disease entities with speciiie prognostic criteria [J]. Bone Marrow Transplant, 2001.28(1):29- 37.
10Elomaa I,Joensuu H,Blomqvist C.Vinorelbine,methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer:a randomized phase Ⅱ trim[J].Ann Oncol,2003,14:699～703.
9Palumbo A,Avonto I,Bruno B. Intravenous melphalan,thalidomide and prednisone in refractory and relapsed multiple myeloma[J].European Journal of Haematology,2006,(04):273-277.
10Kropff M,Baylon HG,Hillengass J. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma:results from OPTIMUM,a randomized trial[J].Haematologica,2012,(05):784-791.
